FBIO Latest News

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

globenewswire.com — Mar 31, 2026

ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priorit

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

globenewswire.com — Mar 30, 2026

MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics,

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

globenewswire.com — Mar 25, 2026

Total revenues were $61. 9 million in FY2025 compared to $56.

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

globenewswire.com — Mar 18, 2026

Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p. m.

Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next?

defenseworld.net — Mar 11, 2026

Fortress Biotech, Inc. (NASDAQ: FBIO - Get Free Report)'s share price crossed above its 200-day moving average during trading on Tuesday.